Table 3.
Gene-gene interaction: +61 A>G EGF (rs4444903) and +142285 G>A EGFR (rs2227983) between study groups (n = 407), age- and sex-adjusted.
| EGF-EGFR interaction | Group 2 n = 106 |
Group 1 n = 301 |
Group 1 vs. Group 2 ORadj (95% CI) |
p value | ||
|---|---|---|---|---|---|---|
| EGF-EGFR ∗ | 38 | 35.8% | 91 | 30.2% | 1.00 (ref.) | |
| AA-AA | 3 | 2.8% | 10 | 3.3% | 1.44 (0.35-5.94) | 0.614 |
| AA-AG | 7 | 6.6% | 39 | 13.0% | 2.43 (0.96-6.13) | 0.060 |
| AA-GG | 26 | 24.5% | 69 | 22.9% | 1.17 (0.63-2.17) | 0.625 |
| AG-GG | 25 | 23.6% | 70 | 23.3% | 1.25 (0.67-2.33) | 0.489 |
| GG-GG | 7 | 6.6% | 22 | 7.3% | 1.41 (0.52-3.81) | 0.497 |
Adj: adjusted OR for age and sex; CI: confidence interval; EGF: epidermal growth factor; EGFR: epidermal growth factor receptor; NERD: nonerosive reflux disease group; OR: odds ratio; ∗reference genotypes EGF-EGFR (AG-AA, AG-AG, GG-AA, and GG-AG) according to Upadhyay et al. [27]; Group 1: patients with diagnosis RE, BE, or EAC determined by a pathologist; Group 2: patients without macroscopical changes of the esophageal mucosa and with/without NERD (including healthy individuals).